Skip to main content Skip to journal navigation menu Skip to site footer
contact@ukscip.com
Article

Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine

Mohd Afzal ,  Ashok Kumar Sah ,  Shagun Agarwal ,  Akifa Tanzeel ,  Rabab H. Elshaikh ,  Fawzia Abdalla Alobeidli ,  Ayman Hussein Alfeel ,  Ranjay Kumar Choudhary ,  Ajabsingh Choudhary
    Received: 03 January 2025
    Published: 21 November 2014

    Abstract

    The incorporation of artificial intelligence (AI) into medical practice has considerably improved the treatment of autoimmune disorders, opening new avenues for personalized therapy. This study examines advances in AI-driven therapeutic options for autoimmune illnesses, including both current and developing treatments. Traditional therapies for autoimmune illnesses, such as immunosuppressive therapy and biologics, attempt to alleviate symptoms but frequently fall short of offering personalized care. Emerging approaches, such as precision medicine and artificial intelligence, are altering the landscape by harnessing massive volumes of patient data to better customize therapies. AI holds the ability to transform autoimmune disease therapy by enhancing diagnosis, discovering biomarkers, optimizing drug development, and personalized treatment procedures. Real-world applications and case studies are examined to demonstrate how machine learning algorithms have improved treatment tactics for rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. While AI has many advantages, like enhanced diagnosis accuracy and personalized therapy, it also has drawbacks, such as data privacy, the requirement for vast datasets, algorithmic bias, and a lack of explain ability. This study emphasizes the advantages of AI, such as improved patient stratification and predictive modelling, while also discussing its drawbacks, such as ethical problems and the possibility of data exploitation. AI presents intriguing prospects for treating autoimmune diseases, but more research and cooperation are required to overcome current difficulties and completely integrate AI into clinical practice.

    Keywords

    References

    1. 1. Mackay IR. Autoimmune Diseases. Encyclopedia of Immunology. Published online 1998: 287–292. doi: 10.1006/rwei.1999.0074
    2. 2. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunology today. 1993; 14(9): 426–430.
    3. 3. Davidson A, Diamond B. Autoimmune Diseases. Mackay IR, Rosen FS, eds. New England Journal of Medicine. 2001; 345(5): 340–350. doi: 10.1056/nejm200108023450506
    4. 4. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Frontiers in Neuroendocrinology. 2014; 35(3): 347–369. doi: 10.1016/j.yfrne.2014.04.004
    5. 5. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. Journal of Clinical Investigation. 2015; 125(6): 2228–2233. doi: 10.1172/jci78088
    6. 6. Ghobadinezhad F, Ebrahimi N, Mozaffari F, et al. The emerging role of regulatory cell-based therapy in autoimmune disease. Frontiers in Immunology. 2022; 13. doi: 10.3389/fimmu.2022.1075813
    7. 7. Pisetsky DS. Pathogenesis of autoimmune disease. Nature Reviews Nephrology. 2023; 19(8): 509–524. doi: 10.1038/s41581-023-00720-1
    8. 8. Vivas AJ, Boumediene S, Tobón GJ. Predicting autoimmune diseases: A comprehensive review of classic biomarkers and advances in artificial intelligence. Autoimmunity Reviews. 2024; 23(9): 103611. doi: 10.1016/j.autrev.2024.103611
    9. 9. Ahmed Z. Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities. Emerging Topics in Life Sciences. 2022; 6(2): 215–225. doi: 10.1042/etls20210244
    10. 10. Sahu A, Mishra J, Kushwaha N. Artificial Intelligence (AI) in Drugs and Pharmaceuticals. Combinatorial Chemistry & High Throughput Screening. 2022; 25(11): 1818–1837. doi:10.2174/1386207325666211207153943
    11. 11. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Research & Therapy. 2010; 13(1): 101. doi: 10.1186/ar3204
    12. 12. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017; 389(10086): 2338–48.
    13. 13. Dias SS, Isenberg DA. Advances in systemic lupus erythematosus. Medicine. 2014; 42(3): 126–133. doi: 10.1016/j.mpmed.2013.12.013
    14. 14. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the
    15. 15. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple Sclerosis. New England Journal of Medicine. 2000; 343(13): 938–952. doi: 10.1056/nejm200009283431307
    16. 16. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity reviews. 2003;2(3): 119–125.
    17. 17. Petersen JS, Dyrberg T, Karlsen AE, Molvig J. Type 1 (insulin-dependent) diabetes mellitus: an overview of autoimmune disease and the role of interleukin-1. Diabetologia. 1997; 40(Suppl 2): S26–S34.
    18. 18. Lerner A, Jeremias P, Matthias T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2015; 3(4): 151–155. doi: 10.12691/ijcd-3-4-8
    19. 19. Baldini E, Odorisio T, Tuccilli C, et al. Thyroid diseases and skin autoimmunity. Reviews in Endocrine and Metabolic Disorders. 2018; 19(4): 311–323. doi: 10.1007/s11154-018-9450-7
    20. 20. Singh M, Wambua S, Lee SI, et al. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. BMC Medicine. 2024; 22(1): 94. doi: 10.1186/s12916-024-03309-y
    21. 21. Kronzer VL, Kimbrough BA, Crowson CS, et al. Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study. Arthritis Care & Research. 2022; 75(2): 348–355. doi: 10.1002/acr.24786
    22. 22. Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. The Lancet Regional Health—Western Pacific. 2020; 5: 100063. doi: 10.1016/j.lanwpc.2020.100063
    23. 23. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmunity Reviews. 2014; 13(4–5): 391–397. doi: 10.1016/j.autrev.2014.01.007
    24. 24. Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population—based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR ). British Journal of Dermatology. 2020; 182(5): 1158–1166. doi: 10.1111/bjd.18333
    25. 25. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nature Reviews Endocrinology. 2013; 9(12): 724–734. doi: 10.1038/nrendo.2013.193
    26. 26. Bai JC, Ciacci C. World Gastroenterology Organisation Global Guidelines. Journal of Clinical Gastroenterology. 2017; 51(9): 755–768. doi: 10.1097/mcg.0000000000000919
    27. 27. Bugălă NM, Carsote M, Stoica LE, et al. New Approach to Addison Disease: Oral Manifestations Due to Endocrine Dysfunction and Comorbidity Burden. Diagnostics. 2022; 12(9): 2080. doi: 10.3390/diagnostics12092080
    28. 28. Voulgaris TA, Karamanolis GP. Esophageal manifestation in patients with scleroderma. World Journal of Clinical Cases. 2021; 9(20): 5408–5419. doi: 10.12998/wjcc.v9.i20.5408
    29. 29. Stavropoulos PG, Soura E, Kanelleas A, et al. Reactive Arthritis. Journal of the European Academy of Dermatology and Venereology. 2015; 29(3): 415–424. doi: 10.1111/jdv.12741
    30. 30. Benagiano M, Bianchi P, D’Elios MM, et al. Autoimmune diseases: Role of steroid hormones. Best Practice & Research Clinical Obstetrics & Gynaecology. 2019; 60: 24–34. doi: 10.1016/j.bpobgyn.2019.03.001
    31. 31. Williams DM. Clinical Pharmacology of Corticosteroids. Respiratory Care. 2018; 63(6): 655–670. doi: 10.4187/respcare.06314
    32. 32. Reichardt SD, Amouret A, Muzzi C, et al. The Role of Glucocorticoids in Inflammatory Diseases. Cells. 2021; 10(11): 2921. doi: 10.3390/cells10112921
    33. 33. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Alimentary Pharmacology & Therapeutics. 2014; 39(5): 459–477. doi: 10.1111/apt.12616
    34. 34. Christofi T, Baritaki S, Falzone L, et al. Current Perspectives in Cancer Immunotherapy. Cancers. 2019; 11(10): 1472. doi: 10.3390/cancers11101472
    35. 35. Feldmann M, Maini RN. Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned? Annual Review of Immunology. 2001; 19(1): 163–196. doi: 10.1146/annurev.immunol.19.1.163
    36. 36. Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. Journal of Psoriasis and Psoriatic Arthritis. 2018; 4(2): 70–80. doi: 10.1177/2475530318810851
    37. 37. Thoma LM, Li LC, White DK, et al. Physical Therapists Play a Key Role in the Comprehensive Management of Rheumatoid Arthritis. Arthritis Care & Research. 2023; 75(8): 1625–1628. doi: 10.1002/acr.25123
    38. 38. Göksel Karatepe A, Günaydin R, Türkmen G, et al. Effects of home-based exercise program on the functional status and the quality of life in patients with rheumatoid arthritis: 1-year follow-up study. Rheumatology International. 2009; 31(2): 171–176. doi: 10.1007/s00296-009-1242-7
    39. 39. Vojdani A, O’Bryan T, Green JA, et al. Immune Response to Dietary Proteins, Gliadin and Cerebellar Peptides in Children with Autism. Nutritional Neuroscience. 2004; 7(3): 151–161. doi: 10.1080/10284150400004155
    40. 40. Skoldstam L, Hagfors L, Johansson G.. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003; 62(3): 208–214. doi: 10.1136/ard.62.3.208
    41. 41. Sharif K, Watad A, Bragazzi NL, et al. Physical activity and autoimmune diseases: Get moving and manage the disease. Autoimmunity Reviews. 2018; 17(1): 53–72. doi: 10.1016/j.autrev.2017.11.010
    42. 42. Schäfer C, Keyßer G. Lifestyle Factors and Their Influence on Rheumatoid Arthritis: A Narrative Review. Journal of Clinical Medicine. 2022; 11(23): 7179. doi: 10.3390/jcm11237179
    43. 43. Dammes N, Peer D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. Theranostics. 2020; 10(2): 938–955. doi: 10.7150/thno.37443
    44. 44. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010; 70(8): 1059–1078. doi: 10.2165/11205090-000000000-00000
    45. 45. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021; 9(6): 643–654. doi: 10.1016/S2213-2600(21)00103-X
    46. 46. O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases. 2013; 72(suppl 2): ii111–ii115. doi: 10.1136/annrheumdis-2012-202576
    47. 47. Nash RA, Hutton GJ, Racke MK, et al. High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology. 2015; 72(2): 159. doi: 10.1001/jamaneurol.2014.3780
    48. 48. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology. 2012; 12(5): 383–396. doi: 10.1038/nri3209
    49. 49. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011; 378(9790): 498–506. doi: 10.1016/S0140-6736(11)60982-3
    50. 50. Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet. 2013; 381(9872): 1116–1124. doi: 10.1016/S0140-6736(12)62114-X
    51. 51. Choi EW, Lee HW, Shin IS, et al. Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus. Cell Transplantation. 2016; 25(6): 1193–1206. doi: 10.3727/096368915x689442
    52. 52. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213). doi: 10.1126/science.1258096
    53. 53. Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Current Opinion in Immunology. 2009; 21(2): 215–223. doi: 10.1016/j.coi.2009.02.009
    54. 54. Singh DD, Hawkins RD, Lahesmaa R, et al. CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases. Seminars in Cell & Developmental Biology. 2019; 96: 32–43. doi: 10.1016/j.semcdb.2019.05.007
    55. 55. Van Zeebroeck L, Arroyo Hornero R, Côrte-Real BF, et al. Fast and Efficient Genome Editing of Human FOXP3+ Regulatory T Cells. Frontiers in Immunology. 2021; 12. doi: 10.3389/fimmu.2021.655122
    56. 56. Dai X, Blancafort P, Wang P, et al. Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine. Advanced Science. 2020; 7(12). doi: 10.1002/advs.201902552
    57. 57. Bhattacharjee G, Gohil N, Khambhati K, et al. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of Controlled Release. 2022; 343: 703–723. doi: 10.1016/j.jconrel.2022.02.005
    58. 58. Guttinger S. Trust in Science: CRISPR–Cas9 and the Ban on Human Germline Editing. Science and Engineering Ethics. 2018; 24(4): 1077–1096. doi: 10.1007/s11948-017-9931-1
    59. 59. Gyngell C, Douglas T, Savulescu J. The Ethics of Germline Gene Editing. Journal of Applied Philosophy. 2017; 34(4): 498–513. doi: 10.1111/japp.12249
    60. 60. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017; 46(2): 183–196. doi: 10.1016/j.immuni.2017.02.006
    61. 61. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases. 2020; 79(6): 685–699. doi: 10.1136/annrheumdis-2019-216655
    62. 62. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002; 96(1): 23–43. doi: 10.1016/s0163-7258(02)00297-8
    63. 63. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents. Autoimmunity Reviews. 2010; 9(3): 188–193. doi: 10.1016/j.autrev.2009.10.003
    64. 64. Robin DiMatteo M, Giordani PJ, Lepper HS, et al. Patient Adherence and Medical Treatment Outcomes. Medical Care. 2002; 40(9): 794–811. doi: 10.1097/00005650-200209000-00009
    65. 65. Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? International Journal of Clinical Rheumatology. 2015; 10(5): 345–356. doi: 10.2217/ijr.15.39
    66. 66. Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases. Trends in Pharmacological Sciences. 2023; 44(7): 411–424. doi: 10.1016/j.tips.2023.04.005
    67. 67. Gerussi A, Scaravaglio M, Cristoferi L, et al. Artificial intelligence for precision medicine in autoimmune liver disease. Frontiers in Immunology. 2022; 13. doi: 10.3389/fimmu.2022.966329
    68. 68. Lundervold AS, Lundervold A. An overview of deep learning in medical imaging focusing on MRI. Zeitschrift für Medizinische Physik. 2019; 29(2): 102–127. doi: 10.1016/j.zemedi.2018.11.002
    69. 69. Miotto R, Wang F, Wang S, et al. Deep learning for healthcare: review, opportunities and challenges. Briefings in Bioinformatics. 2017; 19(6): 1236–1246. doi: 10.1093/bib/bbx044
    70. 70. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019; 25(1): 44–56. doi: 10.1038/s41591-018-0300-7
    71. 71. MacEachern SJ, Forkert ND. Machine learning for precision medicine. Genome. 2021; 64(4): 416–425. doi: 10.1139/gen-2020-0131
    72. 72. Zhavoronkov A. Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. Molecular Pharmaceutics. 2018; 15(10): 4311–4313. doi: 10.1021/acs.molpharmaceut.8b00930
    73. 73. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. Nature Materials. 2019; 18(5): 435–441. doi: 10.1038/s41563-019-0338-z
    74. 74. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019; 24(3): 773–780. doi: 10.1016/j.drudis.2018.11.014
    75. 75. Davergne T, Rakotozafiarison A, Servy H, et al. Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020? Sensors. 2020; 20(17): 4797. doi: 10.3390/s20174797
    76. 76. Kamei T, Kanamori T, Yamamoto Y, et al. The use of wearable devices in chronic disease management to enhance adherence and improve telehealth outcomes: A systematic review and meta-analysis. Journal of Telemedicine and Telecare. 2020; 28(5): 342–359. doi: 10.1177/1357633x20937573
    77. 77. Keesara S, Jonas A, Schulman K. Covid-19 and Health Care’s Digital Revolution. New England Journal of Medicine. 2020; 382(23). doi: 10.1056/nejmp2005835
    78. 78. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 2023; 23(1): 689. doi: 10.1186/s12909-023-04698-z
    79. 79. Yagin F, Alkhateeb A, Raza A, et al. An Explainable Artificial Intelligence Model Proposed for the Prediction of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Identification of Distinctive Metabolites. Diagnostics. 2023; 13(23): 3495. doi: 10.3390/diagnostics13233495
    80. 80. Vodencarevic A, Tascilar K, et al. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Research & Therapy. 2021; 23(1). doi: 10.1186/s13075-021-02439-5
    81. 81. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017; 542(7639): 115–118. doi: 10.1038/nature21056
    82. 82. Momtazmanesh S, Nowroozi A, Rezaei N. Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-of-the-Art Review. Rheumatology and Therapy. 2022; 9(5): 1249–1304. doi: 10.1007/s40744-022-00475-4
    83. 83. Mukherjee S, Suleman S, Pilloton R, et al. State of the Art in Smart Portable, Wearable, Ingestible and Implantable Devices for Health Status Monitoring and Disease Management. Sensors. 2022; 22(11): 4228. doi: 10.3390/s22114228
    84. 84. Wang S, Hou Y, Li X, et al. Practical Implementation of Artificial Intelligence-Based Deep Learning and Cloud Computing on the Application of Traditional Medicine and Western Medicine in the Diagnosis and Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology. 2021; 12. doi: 10.3389/fphar.2021.765435
    85. 85. Danieli MG, Brunetto S, Gammeri L, Palmeri D, Claudi I, Shoenfeld Y, Gangemi S. Machine learning application in autoimmune diseases: State of art and future prospectives. Autoimmun Rev. 2024 Feb;23(2):103496. doi: 10.1016/j.autrev.2023.103496.
    86. 86. Zhang P, Fonnesbeck C, Schmidt DC, et al. Using Momentary Assessment and Machine Learning to Identify Barriers to Self-management in Type 1 Diabetes: Observational Study. JMIR mHealth and uHealth. 2022; 10(3): e21959. doi: 10.2196/21959
    87. 87. Kahkoska AR, Shah KS, Kosorok MR, et al. Estimation of a Machine Learning-Based Decision Rule to Reduce Hypoglycemia Among Older Adults With Type 1 Diabetes: A Post Hoc Analysis of Continuous Glucose Monitoring in the WISDM Study. Journal of Diabetes Science and Technology. 2024; 18(5): 1079–1086. doi: 10.1177/19322968221149040
    88. 88. Pillai AS. Utilizing Deep Learning in Medical Image Analysis for Enhanced Diagnostic Accuracy and Patient Care: Challenges, Opportunities, and Ethical Implications. Journal of Deep Learning in Genomic Data Analysis. 2021; 1(1): 1–7.
    89. 89. Johnson KB, Wei W, Weeraratne D, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clinical and Translational Science. 2021; 14(1): 86–93. doi: 10.1111/cts.12884
    90. 90. Yadav S, Singh A, Singhal R, et al. Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intelligent Pharmacy. 2024; 2(3): 367–380. doi: 10.1016/j.ipha.2024.02.009
    91. 91. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 2023; 23(1): 689. doi: 10.1186/s12909-023-04698-z
    ×